ALK antibody (AA 200-335)

Catalog No. ABIN6654203

Product Details anti-ALK Antibody

Target: ALK (Anaplastic Lymphoma Receptor tyrosine Kinase (ALK))

Binding Specificity: AA 200-335

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This ALK antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: Purified

Purity: Protein G affinity

Immunogen: A portion of amino acids 200-335 from the human protein was used as the immunogen for this ALK antibody.

Clone: ALK-1504

Isotype: IgG2b kappa

Application Details

Application Notes: The stated application concentrations are suggested starting amounts. Titration of the ALK antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. IHC (FFPE): 1-2 μg/mL for 30 min at RT

Restrictions: For Research Use only

Handling

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the recombinant ALK antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for ALK

Target: ALK (Anaplastic Lymphoma Receptor tyrosine Kinase (ALK))

Alternative Name: ALK / Anaplastic Lymphoma Kinase (ALK Products)

Background: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200 kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,  NPM-ALK, created by the t(2,5)(p23,q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80 kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5 % -10 % of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control.

Pathways: RTK Signaling